Suppr超能文献

马来西亚公立医院乳腺癌患者使用补充和替代医学(CAM)情况以及就诊和诊断延迟情况

Complementary and alternative medicine (CAM) use and delays in presentation and diagnosis of breast cancer patients in public hospitals in Malaysia.

作者信息

Mohd Mujar Noor Mastura, Dahlui Maznah, Emran Nor Aina, Abdul Hadi Imisairi, Wai Yan Yang, Arulanantham Sarojah, Hooi Chea Chan, Mohd Taib Nur Aishah

机构信息

Cluster of Healthy Lifestyle, Advanced Medical and Dental Institute, University Science of Malaysia, Penang, Malaysia.

Department of Social & Preventive Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.

出版信息

PLoS One. 2017 Apr 27;12(4):e0176394. doi: 10.1371/journal.pone.0176394. eCollection 2017.

Abstract

Complementary and alternative medicine (CAM) is widely used among the breast cancer patients in Malaysia. Delays in presentation, diagnosis and treatment have been shown to impact the disease prognosis. There is considerable use of CAM amongst breast cancer patients. CAM use has been cited as a cause of delay in diagnosis and treatments in qualitative studies, however there had not been any confirmatory study that confirms its impact on delays. The purpose of this study was to evaluate whether the use of CAM among newly diagnosed breast cancer patients was associated with delays in presentation, diagnosis or treatment of breast cancer. This multi-centre cross-sectional study evaluating the time points of the individual breast cancer patients' journey from first visit, resolution of diagnosis and treatments was conducted in six public hospitals in Malaysia. All newly diagnosed breast cancer patients from 1st January to 31st December 2012 were recruited. Data were collected through medical records review and patient interview by using a structured questionnaire. Complementary and alternative medicine (CAM) was defined as the use of any methods and products not included in conventional allopathic medicine before commencement of treatments. Presentation delay was defined as time taken from symptom discovery to first presentation of more than 3 months. The time points were categorised to diagnosis delay was defined as time taken from first presentation to diagnosis of more than 1 month and treatment delay was defined as time taken from diagnosis to initial treatment of more than 1 month. Multiple logistic regression was used for analysis. A total number of 340 patients participated in this study. The prevalence of CAM use was 46.5% (n = 158). Malay ethnicity (OR 3.32; 95% CI: 1.85, 5.97) and not interpreting symptom as cancerous (OR 1.79; 95% CI: 1.10, 2.92) were significantly associated with CAM use. The use of CAM was associated with delays in presentation (OR 1.65; 95% CI: 1.05, 2.59), diagnosis (OR 2.42; 95% CI: 1.56, 3.77) and treatment of breast cancer (OR 1.74; 95% CI: 1.11, 2.72) on univariate analyses. However, after adjusting with other covariates, CAM use was associated with delays in presentation (OR 1.71; 95% CI: 1.05, 2.78) and diagnosis (OR 2.58; 95% CI: 1.59, 4.17) but not for treatment of breast cancer (OR 1.58; 95% CI: 0.98, 2.55). The prevalence of CAM use among the breast cancer patients was high. Women of Malay ethnicity and not interpreting symptom as cancerous were significantly associated with CAM use. The use of CAM is significantly associated with delay in presentation and resolution of diagnosis. This study suggests further evaluation of access to breast cancer care is needed as poor access may cause the use of CAM. However, since public hospitals in Malaysia are heavily subsidized and readily available to the population, CAM use may impact delays in presentation and diagnosis.

摘要

补充和替代医学(CAM)在马来西亚乳腺癌患者中广泛使用。研究表明,就诊、诊断和治疗的延迟会影响疾病预后。乳腺癌患者中大量使用补充和替代医学。在定性研究中,补充和替代医学的使用被认为是导致诊断和治疗延迟的一个原因,然而,尚无任何实证研究证实其对延迟的影响。本研究的目的是评估新诊断乳腺癌患者使用补充和替代医学是否与乳腺癌的就诊、诊断或治疗延迟有关。这项多中心横断面研究在马来西亚的六家公立医院进行,评估了个体乳腺癌患者从首次就诊、诊断明确到治疗的各个时间点。纳入了2012年1月1日至12月31日期间所有新诊断的乳腺癌患者。通过病历审查和使用结构化问卷对患者进行访谈来收集数据。补充和替代医学(CAM)被定义为在开始治疗前使用任何传统对抗疗法未包含的方法和产品。就诊延迟被定义为从发现症状到首次就诊的时间超过3个月。时间点分类如下,诊断延迟被定义为从首次就诊到诊断的时间超过1个月,治疗延迟被定义为从诊断到开始初始治疗的时间超过1个月。采用多元逻辑回归进行分析。共有340名患者参与了本研究。补充和替代医学的使用率为46.5%(n = 158)。马来族裔(OR 3.32;95% CI:1.85,5.97)以及不将症状视为癌症(OR 1.79;95% CI:1.10,2.92)与补充和替代医学的使用显著相关。单因素分析显示,补充和替代医学的使用与乳腺癌的就诊延迟(OR 1.65;95% CI:1.05,2.59)、诊断延迟(OR 2.42;95% CI:1.56,3.77)和治疗延迟(OR 1.74;95% CI:1.11,2.72)相关。然而,在对其他协变量进行调整后,补充和替代医学的使用与就诊延迟(OR 1.71;95% CI:1.05,2.78)和诊断延迟(OR 2.58;95% CI:1.59,4.17)相关,但与乳腺癌治疗延迟无关(OR 1.58;95% CI:0.98,2.55)。乳腺癌患者中补充和替代医学的使用率很高。马来族裔女性以及不将症状视为癌症与补充和替代医学的使用显著相关。补充和替代医学的使用与就诊延迟和诊断延迟显著相关。本研究表明,由于获得乳腺癌护理的机会不佳可能导致补充和替代医学的使用,因此需要进一步评估乳腺癌护理的可及性。然而,由于马来西亚的公立医院得到大量补贴且民众可轻易就诊,补充和替代医学的使用可能会影响就诊和诊断延迟。

相似文献

4
Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study.
PLoS One. 2022 Jan 13;17(1):e0262468. doi: 10.1371/journal.pone.0262468. eCollection 2022.
5
Diagnosis delay of breast cancer and its associated factors in Malaysian women.
BMC Cancer. 2011 Apr 17;11:141. doi: 10.1186/1471-2407-11-141.
7
Complementary alternative medicine use amongst breast cancer patients in the Northern region of peninsular Malaysia.
Asian Pac J Cancer Prev. 2015;16(8):3125-30. doi: 10.7314/apjcp.2015.16.8.3125.
10
The use of complementary and alternative medicine (CAM) among cancer patients at a tertiary hospital in Malaysia.
Complement Ther Med. 2020 May;50:102343. doi: 10.1016/j.ctim.2020.102343. Epub 2020 Mar 8.

引用本文的文献

1
Cicer arietinum extract as antitumor and protective agent against Ehrlich Solid Carcinoma-bearing mice.
BMC Complement Med Ther. 2025 Sep 2;25(1):325. doi: 10.1186/s12906-025-05061-z.
2
Patient journey and timeliness of care for patients with breast cancer in Africa: a scoping review.
BMJ Open. 2025 Aug 31;15(8):e098087. doi: 10.1136/bmjopen-2024-098087.
3
Barriers to Early Breast Cancer Diagnosis in Sudanese Women Before the War.
Breast Cancer (Dove Med Press). 2025 May 20;17:433-445. doi: 10.2147/BCTT.S506724. eCollection 2025.
4
Delay from Onset of Symptoms to Reporting at a Cancer Care Facility and the Impact of Alternate Medicine Usage as a Contributing Factor.
South Asian J Cancer. 2024 Apr 15;14(1):81-85. doi: 10.1055/s-0044-1786003. eCollection 2025 Jan.
10
Development of Predictive Models for Survival among Women with Breast Cancer in Malaysia.
Int J Environ Res Public Health. 2022 Nov 20;19(22):15335. doi: 10.3390/ijerph192215335.

本文引用的文献

1
Use of complementary and alternative medicines among Malaysian cancer patients: A descriptive study.
J Tradit Complement Med. 2015 Mar 18;6(4):321-326. doi: 10.1016/j.jtcme.2014.12.008. eCollection 2016 Oct.
2
The Use of Complementary and Alternative Medicine by Korean Breast Cancer Women: Is It Associated with Severity of Symptoms?
Evid Based Complement Alternat Med. 2015;2015:182475. doi: 10.1155/2015/182475. Epub 2015 Dec 3.
4
Quality of Life in CAM and Non-CAM Users among Breast Cancer Patients during Chemotherapy in Malaysia.
PLoS One. 2015 Oct 9;10(10):e0139952. doi: 10.1371/journal.pone.0139952. eCollection 2015.
6
Complementary alternative medicine use amongst breast cancer patients in the Northern region of peninsular Malaysia.
Asian Pac J Cancer Prev. 2015;16(8):3125-30. doi: 10.7314/apjcp.2015.16.8.3125.
8
Delay in diagnosis and treatment of symptomatic breast cancer in China.
Ann Surg Oncol. 2015 Mar;22(3):883-8. doi: 10.1245/s10434-014-4076-9. Epub 2014 Sep 12.
9
Clinical and prognostic factors associated with diagnostic wait times by breast cancer detection method.
Springerplus. 2014 Mar 6;3:125. doi: 10.1186/2193-1801-3-125. eCollection 2014.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验